NEW YORK–(BUSINESS WIRE)–Omni Eye Services, a leading provider of ophthalmologic services at seven locations in New York and New Jersey, today announced that Dr. Katherine M. Mastrota, Center Director of Omni Eye Surgery in New York City, has written…
Category: Business
Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO
VANCOUVER, British Columbia–(BUSINESS WIRE)–At the 14th Human Proteome Organization World Congress (HUPO), Bruker today announced the new rapifleX MALDI-TOF/TOF mass spectrometer. MALDI-TOF/TOF is established as a powerful tandem mass spectrometry method for in-depth protein analysis. With its redesigned, next-generation TOF/TOF ion optics, the rapifleX system now offers significantly higher speed, mass resolution and mass accuracy. The rapifleX integrates a novel, 10 kHz smartbeam™ 3D scanni
Ocular Therapeutix™ Submits New Drug Application to U.S. Food and Drug Administration for DEXTENZA® for the Treatment of Post-Surgical Ocular Pain
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA® (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of ocular pain following ophthalmic surgery. The data included in the NDA s
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) cells designed to block the progression of the severe dry-form of age-related macular degeneration (AMD), a leading cause of blindness in an aging populatio
Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of RhopressaTM
IRVINE , Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on September 23, dosing commenced of the first patients enrolled in Rocket 4, the Company’s fourth Phase 3 clinical trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with
Research and Markets: Dry Eye Syndrome Forecast in 7 Major Markets 2015-2025 – USA, France, Germany, Italy, Spain, UK and Japan
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/bt4gdd/epiomic) has announced the addition of the “Epiomic Epidemiology Series: Dry Eye Syndrome Forecast in 7 Major Markets 2015-2025” report to their offering. …
Tyrogenex Presents Final Results from Phase 1 Study of X-82 for Wet AMD at the 15th EURETINA Congress
NEEDHAM, Mass., & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, focused on next-gen targeted therapeutics for ophthalmology, presented data from its phase 1 safety study of orally-administered X-82 in patients for wet AMD at EURETINA Congress.
Presbia Flexivue Microlens™ Implanted in More Than 1,000 Patients Worldwide
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic medical device company and leader in near-vision restoration announced today that more than 1000 patients worldwide have been treated with the Presbia Flexivue Microlens™. “We are very pleased to announce this significant milestone,” said Todd Cooper, President and CEO of Presbia. “As we expand the commercialization of our Microlens into additional countries around the world, we are thrilled by the feedback we are receiving from
Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpo
Canon U.S.A. Brings Teleretinal Solutions to Vision Expo West
MELVILLE, N.Y.–(BUSINESS WIRE)–Responding to the growing need for dedicated ophthalmic image management software that is easy to use and can enhance office workflow, while also keeping security and compliance with CMS and HIPAA regulations in mind, C…
NovaBay Pharmaceuticals Signs Agreement with Nation’s Second Largest Independent Optometry Group, ALLDocs
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that the company’s prescription daily eyelid and lash hygiene product Avenova™ will be marketed through ALLDocs Optometry Group, making the product available to the group’s optometrists. ALLDocs, also known as The Association of LensCrafters Leaseholding Doc
Anthem Foundation Impacting Blind and Visually Impaired People Nationwide
COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Anthem Foundation provides a $213,120 grant to the United States Association of Blind Athletes to support more than 500 blind and visually impaired adults in the National Fitness Challenge.
InSite Vision and Sun Pharma Enter into Merger Agreement
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision and Sun Pharma Enter Into Merger Agreement
Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jeffrey S. Heier, M.D., a prominent retinal specialist, has been elected to Ocular’s Board of Directors. Dr. Heier is a leading retinal clinical researcher of new treatments for diseases of the back of the eye, including macular degeneration, diabetic macular edem
Research and Markets: Global Eyewear Market 2015-2019 – Increasing Use of Eyewear as Fashion Statement
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/j9b4zz/global_eyewear) has announced the addition of the “Global Eyewear Market 2015-2019” report to their offering. The global eyewear market to grow during the …
pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO to present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Research and Markets: Pigment Glaucoma – Global Clinical Trials Review, H2, 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/cfp9tk/pigment_glaucoma) has announced the addition of the “Pigment Glaucoma Global Clinical Trials Review, H2, 2015” report to their offering. “Pigment Glaucoma …
Research and Markets: Dry (Atrophic) Macular Degeneration Market – Global Clinical Trials Review, H2, 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/h94frj/dry_atrophic) has announced the addition of the “Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H2, 2015” report to their offering. “Dr…
Research and Markets: Corneal Neovascularization – Global Clinical Trials Review, H2, 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/xglzkh/corneal) has announced the addition of the “Corneal Neovascularization Global Clinical Trials Review, H2, 2015” report to their offering. Corneal Neovascul…
Samenvatting: Novaliq GmbH versterkt uitvoerend bestuur Oliver Schlüter en Hartmut Voss
HEIDELBERG, Germany–(BUSINESS WIRE)–Novaliq GmbH, een farmaceutisch bedrijf dat moeilijk oplosbare medicijnen omvormt tot effectieve oogheelkundige therapieën, heeft vandaag bekendgemaakt dat Oliver Schlüter het bedrijf versterkt als algemeen directeur en financieel bestuurder. Daarnaast benoemt Novaliq Hartmut Boss tot hoofd bedrijfszaken. Dr. Schlüter was eerder financieel directeur van CureVac, waar hij een groot aandeel had in de transformatie een zeventig werknemers tellend onderzoeksbed